JW Holdings

Sepsis refers to organ failure caused by disorders of the body's immune response regulation caused by infection, and is one of the high mortality diseases with 30 million cases worldwide each year. It is the most common disease in the intensive care unit in Korea. Currently, rapid response and continuous monitoring through early diagnosis are the only way to reduce sepsis mortality. WRS is a type of aminoacyl tRNA synthetase (ARS) that is primarily responsible for the synthesis of proteins in the body. In 2016, the world's first new cell regulatory network was identified at Nature microbiology, demonstrating its potential as a sepsis diagnostic biomarker. In this paper, we found that WRS is rapidly expressed in sepsis patients and can be diagnosed as sepsis due to various infections (bacteria, fungi, viruses). In-house clinical studies have shown that WRS reflects sepsis severity as well as high diagnostic accuracy.

• Method of detecting a composition and diagnostic marker for diagnosing an infectious disease or complication using tryptophanyl tRNA synthase (2016)
  Registered in K (10-1771697)
  Patent application is filed (US/EP/JP/CN) and under examination.
• Antibodies that specifically bind to WRS proteins and uses thereof (2019)
  (10-2019-0087230, 10-2019-0087233)

Pancreatic cancer is the fourth highest death rate in the world and fifth in the country, with a five-year survival rate of only 10 percent. Pancreatic cancer has no initial symptoms and is difficult to detect, and is mostly diagnosed at the end of the year, except for early detection, has a poor prognosis and a high mortality rate. Early diagnosis is essential to reduce the mortality of pancreatic cancer, but carbohydrate antigen 19-9 (CA19-9) currently used as a pancreatic cancer diagnostic biomarker is less accurate for early diagnosis.

The technology for multi-viomarker analysis using the new pancreatic cancer biomarker, B (CFB) and CA19-9, has been found to improve the accuracy of the existing pancreatic cancer diagnosis biomarker, CA19-9. In addition, early diagnosis of pancreatic cancer has been proven possible.

Diagnostic Values of CA 19-9 and CFB According to Cut-off Levels in PC versus Other Disease

¹Sensitivity and specificity of the combination of CFB and CA 19-9 from the maximum Youden’s index.
²Predicted optimal cut-off value from the maximum Youden’s index.
Abbreviations: CA19-9: carbohydrate antigen 19-9; CFB: complement factor b; PC: pancreatic cancer; Others: HD (healthy donor), CP (chronic pancreatitis), HCC (hepatocellular carcinoma), CC (cholangiocarcinoma), GC (gastric cancer)

Identification of Human Complement Factor B as a Novel Biomarker Candidate for Pancreatic Ductal Adenocarcinoma J Proteome Res. 2014 Nov 7;13(11):4878-88

• Pancreatic cancer diagnostic kit including antibody that specifically binds to complement factor B protein (Registration No. 10-1594287)
• Patent registered in KR/EP/JP/CN/US